1 / 39

Hormonale adjuvante behandeling van mammacarcinoom onder de veertig

Hormonale adjuvante behandeling van mammacarcinoom onder de veertig. Jan H. Schornagel Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Amsterdam, 28-6-2006. Hormonale adjuvante behandeling van mammacarcinoom onder de veertig. Indicaties Keuze van therapie Bijwerkingen

pakuna
Download Presentation

Hormonale adjuvante behandeling van mammacarcinoom onder de veertig

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Hormonale adjuvante behandeling van mammacarcinoom onder de veertig Jan H. Schornagel Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Amsterdam, 28-6-2006

  2. Hormonale adjuvante behandeling van mammacarcinoom onder de veertig • Indicaties • Keuze van therapie • Bijwerkingen • Specifieke problemen

  3. Hormonale adjuvante behandeling van mammacarcinoom onder de veertig • Indicaties • Keuze van therapie • Bijwerkingen • Specifieke problemen

  4. Onafhankelijke Risicofactoren • Tumorgrootte • Gradering volgens Bloom en Richardson • N+ • Leeftijd  35

  5. Indicaties adjuvante hormonale therapie onder de 40 • Uitsluitend indien ER+ en/of PgR+ • N+ tumoren • N- én  1 cm én SBR II of III én  35 jaar • N- én  1 cm én  35 jaar • N- én 1-2 cm én SBR III • N- én 2-3 cm SBR II of III • N- én  3 cm Richtlijn Behandeling van het Mammacarcinoom 2005

  6. Hormonale adjuvante behandeling van mammacarcinoom onder de veertig • Indicaties • Keuze van therapie • Bijwerkingen • Specifieke problemen

  7. Hormonale adjuvante therapie bij premenopauzale vrouwen Tamoxifen LHRH analoga LHRH analoga + Tamoxifen Richtlijn Behandeling van het Mammacarcinoom 2005

  8. Fig 2. Overall survival stratified by study Klijn, J. G.M. et al. J Clin Oncol; 19:343-353 2001

  9. Op basis van deze gegevens wordt tegenwoordig tamoxifen vrijwel standaard gecombineerd met een LHRH agonist in de adjuvante hormonale behandeling van premenopauzale vrouwen.

  10. Is dat wel “evidence based medicine”?

  11. Nee, er is hooguit “circumstantial evidence”

  12. Adjuvant goserelin in pre-menopausal patients with early breast cancer: Results from the ZIPP study. M. Baum, A. Hackshaw, J. Houghton, L.E. Rutqvist, B. Nordenskold, A. Nicolucci, R. Sainsbury, ZIPP International Collaborators Group European Journal of Cancer 2006;42:895-904

  13. The ZIPP (Zoladex In Premenopausal Patients) study was designed to determine whether addition of goserelin and/or tamoxifen to adjuvant therapy (radiotherapy and/or chemotherapy), provided benefit to pre- or peri-menopausal women with operable, early breast cancer. Between 1987 and 1999 a total of 2710 patients were recruited from the four trial groups (CRUK, Stockholm, SE Sweden, GIVIO).

  14. Fig. 1 The distribution of patients in the ZIPP trial (n=2710)

  15. ZIPP study: Kaplan-Meier curves of overall survivalM.Baum et al. Eur J Cancer (2006) 42:895-904

  16. ZIPP Trial: Conclusion “The effect on survival was similar in patients who received tamoxifen only and those receiving goserelin only. There was insufficient evidence to conclude whether the effect of the two treatments combined was associated with a greater survival.” M. Baum, et al. Eur J Cancer 2006;42:895-904

  17. Major reported side-effects in the CRUK trial Tamox Zoladex+Tamox N = 463 N = 457 Hot flushes 78 (17) 200 (44) Weight gain 32 (7) 50 (11) Tiredness 10 (2) 12 (3) Headache 5 (1) 21 (5) Pain 9 (2) 11 (3) Nausea/vomiting 0 (0) 4 (<1) Bone pain/arthralgia 4 (1) 11 (2) Anxiety/depression/irritability 10 (2) 26 (6) Sweating 5 (1) 23 (5) Patients with > 1 side effect 189 (41) 297 (65) M. Baum et al. Eur J Cancer 2006;42:895-904

  18. De moraal van het verhaal……

  19. IBCSG 24-02: SOFT P r e m e n o p a u s a l Premeno. ER  10% and/or PgR  10% Patients who continue to be “premenopausal” either after CT or without CT Strata R ANDOMIZE T x 5y OFS + T x 5y OFS + E x 5y Any CT No CT CT=chemotherapy; T=tamoxifen; E=exemestane; OFS=ovarian function suppression using GnRH analogue x 5 years or bilateral oophorectomy or radiation

  20. Hormonale adjuvante behandeling van mammacarcinoom onder de veertig • Indicaties • Keuze van therapie • Bijwerkingen • Specifieke problemen

  21. Side effects of endocrine adjuvant therapy in premenopausal women (1) • Vasomotor symptoms • Vaginal dryness • Sexual dysfunction • Vaginal discharge • Changes in body image • Cognitieve stoornissen • Anxiety and depressive symptoms

  22. Side effects of endocrine adjuvant therapy in premenopausal women (2) Chemical castration with LHRH analogs was associated with the highest level of menopausal symptoms; the effect of tamoxifen was found to be slower and milder. Vasomotor symptoms and vaginal dryness were the most troublesome side effects. Most symptoms were reversible. M Nystedt et al. J Clin Oncol 2003;21:1836

  23. Major reported side-effects in the CRUK trial Tamox Zoladex+Tamox N = 463 N = 457 Hot flushes 78 (17) 200 (44) Weight gain 32 (7) 50 (11) Tiredness 10 (2) 12 (3) Headache 5 (1) 21 (5) Pain 9 (2) 11 (3) Nausea/vomiting 0 (0) 4 (<1) Bone pain/arthralgia 4 (1) 11 (2) Anxiety/depression/irritability 10 (2) 26 (6) Sweating 5 (1) 23 (5) Patients with > 1 side effect 189 (41) 297 (65) M. Baum et al. Eur J Cancer 2006;42:895-904

  24. Treatment of hot flushes • Vitamin E 800 IU/day • Clonidine 25-50 μg a.n. • Venlafaxine 375.5-75 mg/day • Paroxetine 20 mg/day • Gabapentine 900 mg/day None of these is very effective

  25. Hormonale adjuvante behandeling van mammacarcinoom onder de veertig • Indicaties • Keuze van therapie • Bijwerkingen • Specifieke problemen

  26. Specifieke problemen • Optimale duur hormonale therapie • Optimale duur LHRH analoga • Switch na 2½ jaar • Verlies van botmassa • Vaginale oestrogenen veilig?

  27. Aanbevelingen tav potentieel verlies van botmassa • Calciuminname ( 1000 mg/dag) • Adequate vit. D status • Voldoende lichaamsbeweging • Bij hoog risico BMD meting • Eventueel bisfosfonaat (2-5 jaar) Richtlijn Behandeling van het Mammacarcinoom 2005

  28. Figure 1: Serum E2 levels in women receiving concurrent aromatase inhibitors and vaginal estradiol. Kendall, A. et al. Ann Oncol 2006 17:584-587

More Related